ABBVIE
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 507
- Registration Number
- NCT02672852
Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation
Completed
- Conditions
- Genotype 1Chronic Hepatitis C
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 158
- Registration Number
- NCT02669940
Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Adalimumab
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 55
- Registration Number
- NCT02668640
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Phase 3
Completed
- Conditions
- Uterine FibroidsHeavy Menstrual Bleeding
- Interventions
- Drug: Placebo for Estradiol/Norethindrone Acetate
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 413
- Registration Number
- NCT02654054
- Locations
- 🇺🇸
Houston Ctr for Clin Research /ID# 149149, Sugar Land, Texas, United States
🇺🇸Fellows Research Alliance, Inc /ID# 139655, Savannah, Georgia, United States
🇺🇸University of California, Los Angeles /ID# 144107, Los Angeles, California, United States
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection
Phase 3
Completed
- Conditions
- Chronic Hepatitis C Virus (HCV) Infection
- Interventions
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 104
- Registration Number
- NCT02651194
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis
Phase 3
Completed
- Conditions
- Compensated CirrhosisChronic Hepatitis CHepatitis C Virus Infection
- Interventions
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 146
- Registration Number
- NCT02642432
Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C
Completed
- Conditions
- Chronic Hepatitis C
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 394
- Registration Number
- NCT02640547
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
Phase 3
Completed
- Conditions
- Chronic Hepatitis C Virus (HCV) Infection
- Interventions
- Drug: Placebo for ABT-493/ABT-530
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 304
- Registration Number
- NCT02640482
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
Phase 1
Withdrawn
- Conditions
- Chronic Lymphocytic LeukemiaNon-Hodgkin LymphomaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- AbbVie
- Registration Number
- NCT02640833
- Locations
- 🇺🇸
Site Reference ID/Investigator# 148562, Harvey, Illinois, United States
🇺🇸Site Reference ID/Investigator# 147922, Chicago, Illinois, United States
🇺🇸Site Reference ID/Investigator# 145674, Baltimore, Maryland, United States
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
Phase 3
Completed
- Conditions
- Chronic Hepatitis CHepatitis C VirusGenotype 3 Hepatitis C Virus
- Interventions
- First Posted Date
- 2015-12-28
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 506
- Registration Number
- NCT02640157
© Copyright 2025. All Rights Reserved by MedPath